ArticleBlood cancer journal2014
Hairy cell leukemia: short review, today's recommendations and outlook.
Article in Blood cancer journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.The New England journal of medicine · 2015Trial
- Hidden in Plain Sight: Unmasking Hairy Cell Leukemia Through Structured Clinical Reasoning.Cureus · 2026Article
- Hairy Cell Leukemia With Splenic Rupture: Hematological Changes and Disappearance of Hairy Morphology After Splenectomy.Journal of hematology · 2025Article
- Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.NEJM evidence · 2023Article
- The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives.Frontiers in oncology · 2023Review
- A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A.Journal of clinical medicine · 2022Article
- Retrospective Evaluation of Hairy Cell Leukemia Patients: Analysis of a Long-Term Single Center Data.International journal of hematology-oncology and stem cell research · 2022Article
- Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response.Science advances · 2021Review
- Article
- Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis.Orphanet journal of rare diseases · 2020Article
- Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia.Clinical journal of oncology nursing · 2019Review
- Genetic homogeneity of adult Langerhans cell histiocytosis lesions: Insights from BRAFOncology letters · 2017Article
- ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.European journal of endocrinology · 2016Review
- Article
- Hairy cell leukemia: A retrospective study on 11 patients in the Western of Iran.International journal of hematology-oncology and stem cell research · 2015Article
- Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.Cytokine & growth factor reviews · 2015Review
- Efficacy and Safety of Cladribine: Subcutaneous versus Intravenous Administration in Hairy Cell Leukemia Patients.Mediterranean journal of hematology and infectious diseases · 2015Article
- Common and uncommon features of focal splenic lesions on contrast-enhanced ultrasound: a pictorial review.Radiologia brasileiraArticle
- Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hairy cell leukemia (HCL) is part of the low-grade non-Hodgkin lymphoma family and represents approximately 2% of all leukemias. Treatment with splenectomy and interferon-α historically belonged to the first steps of therapeutic options, achieving partial responses/remissions (PR) in most cases with a median survival between 4 and 6 years in the 1980s. The introduction of the purine analogs (PA) pentostatin and cladribine made HCL a well-treatable disease: overall complete response rates (CRR) range from 76 to 98%, with a median disease-free survival (DFS) of 16 years a normal lifespan can be reached and HCL-related deaths are rare. However, insufficient response to PA with poorer prognosis and relapse rates of 30-40% after 5-10 years of follow-up may require alternative strategies. Minimal residual disease can be detected by additional examinations of bone marrow specimens after treatment with PA. The use of immunotherapeutic monoclonal antibodies (mAB) like rituximab as a single agent or in combination with a PA or more recently clinical trials with recombinant immunotoxins (RIT) show promising results to restrict these problems. Recently, the identification of the possible disease-defining BRAF V600E mutation may allow the development of new therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.